Urine Protein to Creatinine Ratio for the Assessment of Bevacizumab-Associated Proteinuria in Patients with Gynecologic Cancers: A Diagnostic and Quality Improvement Study

Proteinuria is a common adverse event arising from treatment with bevacizumab, requiring diagnostic testing via 24-h urine collection. However, this method is cumbersome. We assessed urine screenings in gynecologic cancer patients from February 2021 to May 2022. Along with a simple urine dipstick (U...

Full description

Bibliographic Details

Published in:	Diagnostics
Main Authors:	Kuan-Ju Huang, Wen-Chun Chang, Chi-Hau Chen, Wei-Chen Lin, William Wei-Lin Pan, Hao-I. Hsieh, Yu-Hsiung Hsieh, Lin-Hung Wei, Bor-Ching Sheu
Format:	Article
Language:	English
Published:	MDPI AG 2024-08-01
Subjects:	urine protein to creatinine ratio bevacizumab angiogenesis inhibitors antineoplastic agents proteinuria albuminuria
Online Access:	https://www.mdpi.com/2075-4418/14/17/1852